CIMA LAB Diagnostics is committed to personalized medicine and, to this end, has developed genomic technology based on the analysis of gene panels that allow the identification of predisposition to various types of hereditary cancers. These results help to carry out a more precise follow-up and establish individualized prevention measures for each person.

New panels for the identification of hereditary predisposition to cancer have been developed for the following groups of diseases: 1) Breast and/or ovarian, 2) Digestive, 3) Gastric, 4) Pancreatic, 5) Thyroid and 6) Prostate, among others.

The panels have been developed with NGS (next generation sequencing) technology that allows the detection of all subject alterations (point mutations, indels and changes in the issue copy number) in the complete coding sequence and in relevant promoter regions of the genes analyzed.

To perform these programs of study, it is only necessary a blood sample and perform a enquiry with our geneticists, or other professionals, who collect family and personal history and medical data indicating the realization of this test.

The accumulated experience of the Genomics Unit of CIMA LAB Diagnostics in sporadic and hereditary solid tumors allows the report accompanying the result to include: 1) the clinical interpretation of the genetic variants found, 2) the clinical indication for personalized follow-up and 3) the proposal of risk reduction measures for each individual according to their genetic result .

More information: cimalabdiagnostics@unav.es